. Its role of tumor angiogenesis in cancer stroma is unclear. This study investigated the temporal and spatial expression and the role of miR-126 in the course of cervical carcinogenesis. miR-126 was found to be mainly expressed in the stromal endothelium of the uterine cervix. This downregulation was recapitulated in a cell coculture model, wherein cross talk of cervical cancer cells and fibroblasts induced a downregulation of miR-126 in human umbilical vein endothelial cells, with consequent increase of tube formation. Coinjection of cancer-associated fibroblasts of human cervix enhanced tumorigenesis of cervical cancer cells, with an increase of microvessel density and dye retention in the tumor vasculature. In association with angiogenesis, host-originated miR-126 in these xenograft tumors was progressively downregulated, whereas supplement of the miR-126 precursor in the coinjection suppressed angiogenesis and tumor growth. A proangiogenic gene adrenomedullin (ADM), which was found to be upregulated in the stroma of cervical cancer and which localized mainly in the blood and lymphatic vessels, was identified as a target of inhibition by miR-126 at the carcinoma in situ-to-invasion stage. The study suggests a cancer stroma cross talk induced repression of miR-126 and upregulation of ADM, and probably other proangiogenic factors, to facilitate angiogenesis and invasion growth of cervical cancer.
INTRODUCTION
Carcinogenesis involves active cross talk between cancer cells and stromal cells to develop a supportive microenvironment. 1 A continuous modeling of vasculature in the stroma is essential in tumor development. In the case of carcinogenesis of the uterine cervix, microvessel density in the stroma is positively related to the severity of the cervical intraepithelial neoplasia and invasive cancer. 2, 3 Instead of a smooth, regular branch structure of normal cervix, the vasculature in invasive cervical cancer becomes abundant, chaotic, tortuous and cuffing. 4 In the stroma of developing cervical neoplasia, there is also a progress in the increase of a-smooth muscle actin-expressing fibroblasts, 5 which have been reported to enhance angiogenesis by recruiting endothelial progenitor cells. 6 Many microRNAs are involved in the physiological and pathological processes of angiogenesis and vascular inflammation. 7 The endothelial-specific miR-126 governs angiogenesis and vascular integrity. 8, 9 Repression of miR-126 in the endothelial cells enhances vascular cell adhesion molecule-1 expression and triggers adhesion of leukocytes to the injured vessels to induce inflammatory changes. 10 During atherosclerosis-induced apoptosis in the endothelium, miR-126 is released into the apoptotic bodies and confers a counteraction of apoptosis and recruitment of vascular progenitor cells to the site of injury. 11 Targeted deletion or knockdown of miR-126 in mice and zebrafish results in a loss of integrity and leakiness of vessels during the embryonic period. 9 These vascular phenotypes resemble the vasculature in the developing cancer stroma.
Previous studies of miR-126 in cancer have focused on its expression and roles in cancerous epithelial cells. miR-126 was found to be downregulated and acted as a tumor suppressor in carcinomas of the breast, colon, stomach and pancreas. [12] [13] [14] [15] Restoration of miR-126 in these cancer cells led to growth inhibition 15, 16 or decrease of cellular migration and invasion. 13 Studies of miR-126 in cervical cancer have ended with controversial results. In comparison with normal cervical tissue, Martinez et al. 17 found a relatively low level of miR-126 in cervical cancer cell lines. Another report demonstrated a higher level of miR-126 in cervical cancer tissues when compared with dispase-separated cervical epithelium. 18 As a matter of fact, miR-126 may be most abundantly expressed in the endothelium in the stroma, and its role in tumor angiogenesis has rarely been investigated.
This study investigated the temporal-and spatial-specific expression of miR-126 and its target gene in the developing cervical cancer. By using a cancer cell-fibroblast coculture model and a cancer cell-fibroblast coinjection xenograft model, roles of miR-126 in angiogenesis and tumorigenesis were explored (a diagram of the approaches was shown in Figure 1a) . A cancer-stroma cross talk induced downregulation of miR-126 and upregulation of adrenomedullin (ADM) with subsequent enhancement of angiogenesis, and invasive tumor growth was observed.
RESULTS
Endothelial-specific miR-126 is repressed in the stroma of cervical cancer To localize the expression miR-126 in normal and cancerous uterine cervix, the level of miR-126 was determined in the surface scraping, grossly dissected stroma and the whole tissue of the uterine cervix. As showed in Figure 1b , miR-126 was lowly expressed in cervical scrapings. The level was higher in scrapings from the cancerous cervix than that from the normal cervix (P ¼ 0.01). In contrast, levels of miR-126 were much higher in cervical tissues, dissected cervical stroma and uterine artery. Human umbilical vessel endothelia cells (HUVECs) expressed the highest level. Compared with the normal cervix and cervical stroma, respectively, cervical cancer tissue and cancer stroma expressed significantly lower levels of miR-126 (Po0.001 and P ¼ 0.01, respectively). Expression of miR-126 in the cervical stroma was further localized to the endothelium in the stroma by in situ hybridization (Figure 1c ).
Cancer cell-fibroblast interaction induced downregulation of miR-126, which enhanced tube formation of HUVEC cells We hypothesized that the interaction of cancer cells and the fibroblasts confers downregulation of miR-126 in the endothelium.
To investigate this possibility, we set a triple coculture system wherein primary cultured cervical fibroblasts (normal cervix (NAF)) and CaSki cells were cultured on the two sides of the transwell insert, and were cocultured with HUVEC cells at the bottom of the transwell. The expression of miR-126 in HUVEC cells was repressed in the CaSki-NAF dual culture as compared with that in the NAF-only culture (P ¼ 0.03, Figure 2a ). To further explore the effect of downregulation of miR-126 in angiogenesis, HUVEC cells were transfected with a specific inhibitor, which lowered miR-126 by 73% (Figure 2b ). Lowering of miR-126 in HUVEC cells resulted in a 22% increase of tube formation activity with increased tube length (P ¼ 0.02), number of branch point (P ¼ 0.01) and number of loop (P ¼ 0.009) as compared with the negative control (Figures 2b and c) .
Downregulation of host-derived miR-126 in the fibroblast coinjection xenograft tumor with an increase of tumor vasculature and tumor growth To further clarify the role of miR-126 in the stroma of developing tumor, we conducted a coinjection tumorigenesis model in immune-compromised mice. CaSki cells with or without primarily cultured fibroblasts from the cervical cancer (cancer-associated fibroblast (CAF)) or NAF were injected to the two flanks of Figure 1 . miR-126 is mainly expressed in the vascular endothelium of cervical stroma. (a) The diagram shows study approaches to explore the expression, function and the target gene of miR-126 in the cross talk of cancer cell and the associated fibroblast (CAF). (b) Expression of miR-126 was measured by real-time reverse transcriptase-PCR (RT-PCR) in epithelial scrapings of the normal cervix (n ¼ 16) and cervical cancer (n ¼ 13), in nondissected tissues of normal cervix (n ¼ 16), cervical cancer (n ¼ 14) and in grossly dissected stroma adjacent to the cervical epithelium (normal stroma, n ¼ 8) and to the cervical cancer lesion (cancer stroma, n ¼ 5). Grossly dissected human uterine vessels (n ¼ 4) and HUVEC cells were also measured as positive controls. Quantification of real-time RT-PCR was normalized by internal control RNU43 and was plotted relative to the mean of normal scraping (mean ± s.e.m.). (c) In-situ hybridization with a specific hsa-miR-126 locked nucleic acid probe or scramble probe was performed in the stroma of the normal cervix. miR-126 was highly expressed in vascular endothelium (black arrows). *Po0.05 and ***Po0.001 (by Mann-Whitney' s test).
NOD-SCID (non-obese diabetic, severe-combined immunodeficiency) mice for pair-wise comparison. In an optimized fibroblast-to-cancer cell proportion of 1:3 (Supplementary Figure  S2) , fibroblast coinjection tumors were generally larger than those injected with the CaSki cells alone (Figure 3a) . In seven of the eight mice, the level of mature form of miR-126 in the coinjected side was lower than that of the CaSki-alone side ( Figure 3b) .
As mouse and human share an identical mature form miR-126, the species specificity of primary miR-126 was examined in the CAF coinjection tumors. As shown in Figure 3c , mouse-specific or hostoriginated primary miR-126 was much more abundant than the human or tumor-specific one. Along the tumorigenesis, there was a progressive downregulation of the host-specific primary miR-126 and upregulation of the tumor-originated one, which coincided with the clinical observations. Given that host-derived cells represented o7% of the total tumor bulk (Figure 3d ), the density of miR-126 in host-derived cells is expected to be much higher than that in the tumor compartment. We assumed that most of the host-derived cells were tumor-recruited endothelial cells in which miR-126 expression was downregulated.
The microvessel density of the xenograft tumor was stained with a CD31 endothelial cell marker. The CAF coinjection tumors had a significantly higher vessel density than the NAF coinjection tumors (P ¼ 0.01) and the CaSki-alone tumors (Po0.001; Figures 3e and f) . The results demonstrated an interaction of fibroblasts and cancer cells, with a downregulation of miR-126 in host-derived endothelial cells and an increase in tumor vasculature.
Supplement of miR-126 precursor reduced tumor angiogenesis and tumor growth The effect of miR-126 in angiogenesis was further tested in CAF coinjection tumor with supplement of miR-126 precursor or scrambled negative control. The vasculature of the xenograft tumor was investigated by tail-vein injection of Evans blue dye. Compared with the side injected with CaSki-only cell, the side coinjected with CaSki cell and CAF with supplement of scrambled control had a significantly higher vasculature in the tumor (P ¼ 0.012, Figure 4a ). In contrast, when matrigel-mixed miR-126 precursor was added in the coinjection mixture, tumor vasculature was much lower in this side than the CaSki-only-injected side (P ¼ 0.005, Figure 4a ). The tumor weight was also reduced significantly with miR-126 precursor (P ¼ 0.025, Figure 4b ).
ADM is a target of miR-126 ADM is a proangiogenic peptide expressed in multiple tissues, including the endothelium. 19, 20 The 3 0 -untranslated region sequences of human but not of mouse ADM was predicted to be a target of miR-126. We postulated a downregulation of miR-126 might result in loss of repression of ADM, with enhancement of angiogenesis in cervical cancer. We tested the specificity of binding sequences in HeLa cells cotransfected with a luciferase reporter of the predicted binding sequences and an miR-126 precursor (Supplementary Figure S3) . Indeed, miR-126 with the predicted binding sequences conferred a repression of expression, whereas a In seven of the eight mice each, the relative levels of mature form of miR-126 were lower in the side injected with CA þ NAF or CA þ CAF than the side injected with CA alone. (c) Mouse-specific and human-specific primary miR-126 in tumor were measured by real-time reverse transcriptase-PCR, each with species-specific glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control. Lower DC t values (C t of primary miR-126 min GAPDH) or more abundant levels were observed for the mouse-specific than from the human-specific form. A progressive downregulation of the mouse-specific form and upregulation of the human-specific form were observed. (d) To determine the proportion of tumor-and host-derived cells in the xenograft tumor, mean expressional levels of human-and mouse-specific GAPDH mRNA were determined in tumors of different days of growth. The distributional percentage of the two forms showed a low and progressive lowering distributional percentage of mouse mRNA level in the growing tumor. (e) Microvessel density in the tumor was examined by CD31 staining and quantitated by ImageJ program. Tumors of CA þ CAF and CA þ NAF showed higher density of CD31 staining than those of CA alone (scale bar, 10 mm). Increase of stroma vasculature with downregulation of miR-126 and upregulation of ADM at the CIS-to-invasion stage of cervical carcinogenesis Expressions of miR-126 and ADM were further characterized in dissected tissues of cervical cancers. The level of miR-126 was significantly lower in cancer stroma (n ¼ 5) than in normal stroma (n ¼ 8, P ¼ 0.02). In contrast, the level of ADM mRNA was significantly higher in cancer stroma than in normal stroma (P ¼ 0.009; Figure 7a ). The spatial and temporal specificity of expression of miR-126 was further investigated in microdissected stromal and epithelial tissues next to the basal membrane. The level of miR-126 in the near stroma (near to basal membrane) as compared with that in the deep epithelium remained high in the normal cervix and in carcinoma in situ (CIS), but became dramatically lower in the invasive cervical cancer (Figure 7b ). Immunofluorescence staining of the same CIS and invasive cancer cases showed a marked increase of ADM protein, which was colocalized with the CD31-positive endothelium (5. In all the four mice tested, CA þ CAF tumor retained a higher density (as measured by the amount of extracted dye per tumor weight) than the CA-alone tumors (middle panel, n ¼ 4 pairs). Upon adding miR-126 precursor to the coinjection cell mixture, a reverse of this dye retention change was noted in all the tumors (right panel, n ¼ 4 pairs), whereas the negative control oligonucleotide had no effect (left panel, n ¼ 3 pairs). (b) Adding of miR-126 precursor also decreased the weight of the CA þ CAF tumors as compared with that of the control oligonucleotide (n ¼ 8 pairs). *Po0.05, **Po0.01; n.s., no significance.
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DISCUSSION
This study demonstrates a temporal-and spatial-specific downregulation of miR-126 in the stroma of developing human cervical cancer. miR-126 was strongly expressed in the vascular endothelium in the stroma of the uterine cervix. The mean level of miR-126 in cervical stromas was about 300 times greater than that in the cervical scrapings. This difference was mainly attributed to the high expression of miR-126 in stromal vessels. Many studies have reported downregulation of miR-126 in undissected tissues of various cancers as compared with the normal tissues. [13] [14] [15] Here we demonstrate the downregulation of miR-126 in cervical cancer is mainly from the cancer stroma, but not in cancer epithelium, and most likely from the vessels in the stroma.
Although the epithelium component expresses significantly lower miR-126, changes of its expression may still contribute to cancer development. For instance, restoration of miR-126 in various cancer cells inhibits cell growth 15, 16 and reduces cellular migration and invasion, suggesting a tumor suppressor role. 13 Interestingly, we observed an upregulation instead of downregulation of miR-126 in cancer scrapings of the cervix and in the tumor compartment of the xenograft tumor of CaSki cells. The significance of this increase of miR-126 in the transformation of cervical epithelium deserves further investigation.
To investigate the role of miR-126 in tumorigenesis and angiogenesis in an environment of interacting cancer cell and stroma cells, we conducted cell coculture and coinjection xenograft experiments. In the cancer cell-fibroblast-HUVEC cells coculture model, the expression of miR-126 in endothelial cells was repressed by the cancer cell-fibroblast interaction. In the cancer cell-fibroblast coinjection tumor model, fibroblasts derived from both cervical cancer and normal cervix enhanced angiogenesis and tumorigenesis with progressive repression of miR-126. Recent study has reported a downregulation of miR-126 in tumor tissues and surrounding stroma, in association with high tumor angiogenesis. 22 Downregulation of miR-126 in tumor endothelium via cancer cell-CAF cross talk can be an important feature of tumor angiogenesis and tumor growth.
We also studied the level of human-specific and mouse-specific primary miR-126 in the fibroblasts-CaSki cell coinjection xenograft tumor. Human-specific primary miR-126 is supposed to be derived from the carcinoma cells and mouse-specific one is supposed to be derived from host stromal cells, including endothelial cells. In agreement with the findings in clinical specimens, the level of host-derived miR-126 was much higher than that derived from the carcinoma, and the former decreased and the latter increased progressively along the growth of tumor. Previous studies have reported an angiogenic role of CAF by recruiting host endothelial progenitor cells, 6 and cancer cells may exert this angiogenic effect of CAF by a paracrine signaling. 23 The study unveiled a general way of promoting angiogenesis by cancer cell-CAF cross talk, which is accompanied with a downregulation of miR-126 in the tumor endothelial cells.
Further observations in ex-vivo and in-vitro models supported the association of miR-126 downregulation and tumor vessels formation. Turning down of miR-126 resulted in retention of Evans blue dye in the vasculature of CaSki cell-CAF coinjection tumor. Treating HUVEC cells with miR-126 inhibitor led to the formation of more dense and serpentine tube structures. In contrast, adding the miR-126 precursor in the coinjection tumor model readily reversed the vascular dye retention and reduced the tumor size. Meanwhile, using liposome delivery, Bai et al. 24 has demonstrated the restoration of miR-126 in mouse retina with inhibition of abnormal vascular network formation. Gel-mixed miR-126 precursor has been placed around the arteries to limit atherosclerosis in a mouse model. 11 In this study, matrigel-mixed miR-126 precursor was applied in the xenograft. Although it is yet to be known where do these precursors go and how do they work, these precursors worked well in reversion of vasculature and reduced tumor growth in the xenograft model. Vascular normalization by adjusting the miR-126 level can thus be a new strategy of treating cancer.
The study identified ADM as a proangiogenic target of miR-126. miR-126 readily suppress the expression of a reporter construct of a predicted binding sequence at the 3 0 -untranslated region of the ADM gene. A precursor of miR-126 decreased the expression of ADM in a highly expressive cell line, and an inhibitor enhanced the ADM expression in HUVEC cells during tube formation. Interestingly, the miR-126 inhibition-conferred ADM induction in HUVEC cells occurs only when it was under the tube formation, but not in the non-angiogenic state. This finding agrees with the proangiogenic role of miR-126 in the developing vessels.
ADM is a potent, long-acting vasodilator peptide originally isolated from human pheochromocytoma. 25 It affects the vasculature in various ways, including increasing vascular dilatation and permeability, promoting angiogenesis and inhibiting endothelial apoptosis. 26 It contributes to tumor progression and angiogenesis in multiple cancers, 27 and is upregulated in tumor hypoxia state. 28 ADM signaling is also required for normal development of the mouse lymphatic vascular system. 20 A recent study showed a positive correlation of the ADM gene dosage and tumor lymphangiogenesis in mouse lung cancer. 29 In agreement with a previous report, 30 the present study showed an enhancement of tube formation of HUVEC cells by ADM protein.
Meanwhile, a lymphatic-like phenotype was identified in HUVEC cells under tube formation culture. Lymphatic vascular-specific genes, such as LYVE1 31 podoplanin and Prox1, were upregulated when HUVEC cells were cultured in the conventional in-vitro angiogenesis (tube formation) assays in fibrin, collagen or Matrigel. 32 We assume that an increase of ADM following miR-126 repression in cervical carcinogenesis may lead to a differentiation of vascular progenitor cells to both lymphatic or blood vasculature, aiding the development of the cancer. Indeed, we demonstrated a colocalization of ADM with both LYVE-1 and CD31 in the stroma of an early invasive cervical cancer. In grossly dissected and laser-capture microdissection-microdissected epithelium-adjacent stroma of normal cervix and cervical cancer, an inverse expression pattern was noted for miR-126 and ADM (Figures 7a and b) . A dramatic downregulation of miR-126 with overexpression of CD31 and ADM was observed when comparing the stromal tissues of CIS and early invasive cancer (Figure 7c) . Meanwhile, miR-126 was abundantly found in lymph nodes, 33 and lymphatic and blood vascular vessels were increased in the adjacent stroma of the cervical cancer lesion. 34 Thus, loss of miR-126 with resultant overexpression of ADM in both vascular and lymphatic vessels may facilitate angiogenesis and lymphangiogenesis, and the early invasion of cervical cancer.
In addition to ADM, other proangiogenic genes, such as VEGF, ANGPT1 and VCAM1, have been reported as targets of miR-126. 35 ADM confers only partially the proangiogenic phenotype of miR-126 downregulation in the HUVEC cells cross talking with cancer cells and CAF. It is possible that other targets of miR-126 also have roles in the process of miR-126 loss-mediated tumor angiogenesis. Cross talks of tumor cells and its stromal companions, such as fibroblasts and endothelial cells, are complex. In coculture experiments of these cell types, we observed a non-autonomous effect of cancer cell on enhancing the expression of ADM in fibroblasts and endothelial cells. We speculate a signaling of in-situ cancer cell to adjacent stroma with resultant downregulation of the miR-126 host gene EGFL7, and overexpression of multiple proangiogenic targets may be instrumental to the invasion and spreading of CIS to the new microenvironment in the stroma. Meanwhile, macrophages are a rich source of ADM peptide. The study could not exclude the effect of macrophages contributing to the expression of ADM and angiogenesis.
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In summary, the study unveiled a temporal-and spatial-specific downregulation of endothelial-specific miR-126 in the early invasive stage of cervical cancer (Figure 8 ). This downregulation can be mediated by cross talks among cancer cells and adjacent fibroblasts, as well as the angiogenic endothelial cells. The proangiogenic gene ADM is one of the targets to be released from suppression, which aids angiogenesis and, likely, lymphangiogenesis. Thus, targeting on miR-126 can be an innovative means to normalize the aberrant vasculatures in cancer microenvironment.
MATERIALS AND METHODS
The study cohort and clinical specimens Clinical specimens, including cervical scrapings, cervical tissues and uterine vessels, were from a cohort of cervical carcinogenesis in the Tzu Chi General Hospital, Hualien, Taiwan. 36 Scrapings of the surface of the uterine cervix were collected from healthy women receiving routine Pap smear screening and from patients with squamous cell carcinoma of the cervix. This was done on their first visit for pelvic examination before other diagnostic or therapeutic procedures. Cytology of these scrapings revealed a majority of squamous epithelial cell and/or cancer cells. Scrapings were
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collected with a cytobrush and immediately immersed in RNAlater solution (Ambion, Austin, TX, USA), and were frozen before use. Normal cervical tissues were procured from patients receiving total hysterectomy for benign neoplasia of the uterine cervix. Tissues of CIS of the cervix and invasive squamous cell carcinoma of the cervix were procured during operations of cervical conization and radical hysterectomy, respectively. Stromal tissues adjacent to the normal epithelium or to the cancer lesion were dissected grossly. Uterine arteries were also dissected from the uterine specimens. These tissues were collected right after the resection of specimen and were treated with RNAlater or embedded in optical coherence tomography for later use. The Institute Review Board of Tzu Chi General Hospital, Hualien, Taiwan, approved this cohort. Informed consent was signed by each subject.
Procurement of CAF/NAF and cell culture
Stromal tissues adjacent to the cancer lesion and normal epithelium of the uterine cervix were procured for primary culture for CAF and NAF, respectively. After resection of the uterus, the cervical canal was opened to expose the cervical cancer lesion or the squamous-columnar epithelium junction of the normal cervix. A 5-mm-thick stromal tissues adjacent to the cancer lesion or the squamous epithelium near the squamous-columnar epithelium junction were dissected grossly and submitted to primary culture, and were snap-frozen for further analysis. In microscopic examination, the CAF tissues contained a majority of the stromal tissue, with nests of cancer cells infiltration. Tissues were cut to pieces and cultured in Dulbecco's modified Eagle's medium (low glucose) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. CAF in the cell culture were identified by staining of a-smooth muscle actin. CAF was rich in a-smooth muscle actinexpressing cells (7.8%) as compared with NAF (0.69%) (Supplementary Figure S1a) . Notably, NAF and CAF between passage 3 and 8 were used in this study. At these passages, all cells in the culture were fibroblast and were negative for epithelial cytokeratin (Pan) markers (Supplementary Figure S1b) . CaSki and HeLa cells were grown in the RPMI 1640 medium, and the MDA-MB-231 cell was grown in Dulbecco's modified Eagle's medium (high glucose) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Authentication of all human cell lines were examined by DNA STR analysis (Promega, Madison, WI, USA). HUVEC cells and culture medium (endothelial cell medium) were both purchased from SciencCell (Carlsbad, CA, USA). HUVEC cells between passage 4 and 6 were used in this study. All cultured cells were grown at 37 1C and 5% CO 2 .
Triple coculture model A 3-mm Transwell insert (Costar 3452; Corning, NY, USA) was first plated with 10 5 primarily cultured NAF on an inverted position. After 6 h of incubation, inserts were flipped and placed into a six-well Transwell plate, where 3 Â 10 5 CaSki cells were loaded on the other side of the insert and cultured for 24 h. This cancer cell-fibroblast precoated Transwell insert was then placed into another six-well transwell, where 10 5 HUVEC cells had been plated for the same duration of time, and was cultured for additional 2 days before collecting. The upper layer of the transwell was cultured with RPMI 1640 medium and lower layer was cultured with endothelial cell medium at 37 1C and 5% CO 2 .
Real-time reverse transcriptase-PCR assay Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA), following the protocol of the manufacturer. For mature miRNA assay, Figure 5 . ADM is targeted and negatively regulated by miR-126. (a) Normal or mutant sequences of ADM 3 0 -untranslated region (UTR) was constructed downstream to a luciferase reporter (pMir vector), and was cotransfected with a miR-126 precursor or scrambled control to HeLa cells. Renilla control vector was added for transfection efficiency control. Compared with the negative control, the miR-126 precursor inhibited the ADM 3 0 -UTR reporter activity, but not that of a mutant reporter. (b) In the MDA-MB-231 cell, where miR-126 expression is low and ADM expression is high, levels of mRNA of ADM was lowered upon transfection of 30 nM miR-126 precursor as compared with the negative control. (c) Secreted ADM peptide was measured in culture medium of MDA-MB-231 cells 24 h after transfection with negative control, or 10 or 30 nM of the miR-126 precursor. (d) Treatment of HUVEC cells with ADM peptide (10 or 100 nM for 16 h) increased loop numbers, branch points and total tube lengths in the tube formation assay (n ¼ 4). Overall, tube formation activities of the mock, 10 nM ADM and 100 nM ADM groups were 100%, 113.6% and 137.1%, respectively, after a transformation into percentages relative to the mock group. (e) Expression of the ADM gene in HUVEC cells was upregulated 48 h after transfection with 30 nM miR-126 inhibitor. (f ) Forty-eight hours after induction of tube formation in HUVEC cells, the secreted ADM peptide was increased by miR-126 inhibitor transfection in a dose-dependent manner. (g) Forty-eight hours after miR-126 inhibitor transfection, HUVEC cells were seeded on matrigel for tube formation with or without treatment with 1 mM ADM antagonist (ADM 22-52). HUVEC cells transfected with miR-126 inhibitor revealed a higher activity of tube formation, and this activity was only partially inhibited in groups with ADM antagonist treatment. The magnitude of inhibition seemed to be larger in the group transfected with 10 nM miR-126 inhibitor than that with 30 nM (17 vs 12%). The relative tube formation activities of the five groups were 100%, 128%, 111%, 129% and 117%, respectively, after a transformation into percentages relative to control group (n ¼ 3 per group). Data shown are mean ± s.e.m. *Po0.05 and **Po0.01 by Student's t-test. reverse transcription was performed by TaqMan miRNA RT kit (Ambion). Expression of mature mir-126 was quantified by TaqMan miRNA assay and was normalized by small nucleolar RNA, RNU43 (Ambion). For primary microRNAs assay, reverse transcription was performed by Superscript III First-strand synthesis system with oligo-dT primers (Invitrogen). Expression of primary miR-126 was determined by using TaqMan Primary miRNA Role of miR-126 in tumor angiogenesis T-H Huang and T-Y Chu assays (Ambion) with primer sets of Mm03306244_pri for mouse and Hs03303230_pri for human primary miR-126 (Ambion), and mouse-and human-specific GAPDH for normalization. Expressions of ADM was examined by real-time reverse transcriptase-PCR assay, by using the Roche universal probe number 57 (Roche Diagnostic, Mannheim, Germany), with the forward primer of 5 0 -GCCTGCCCAGACCCTTAT-3 0 and the reverse primer of 5 0 -GTAGCGCTTGACTCGGATG-3 0 , respectively. Expression of vascular endothelial growth factor was examined using the forward primer of 5 0 -CTACCTCCACCATGCCAAGT-3 0 and the reverse primer of 5 0 -GCAGTAGCTGCGCTGATAGA-3 0 . Triplicate assays were performed for each sample on Step One-Plus machine (ABI, Foster City, NJ, USA).
In-situ hybridization of miR-126
Biotin-labeled locked nucleic acid probe of has-miR-126 (Exiqon, Vedbaek, Denmark) was applied for in-situ hybridization to detect stromal miR-126 expression. A scrambled locked nucleic acid probe was designed as the negative control. For in-situ hybridization, 8-mm-thin sections of formalinfixed, paraffin-embedded tissues were mounted on Superfrost glass slides and were deparaffinized in xylene baths, followed by serial dilutions in ethanol and diethylpyrocarbonate-treated water bath. In-situ hybridization and signal amplification were performed by Tyramide Signal amplification plus DNP system (PerkinElmer Life Sciences, Waltham, MA, USA), following the manufacturer's protocol.
Cancer cell-fibroblast coinjection tumor model For cancer cell-fibroblast coinjection xenograft model, optimal ratio for tumorigenesis was determined and described in Supplementary Figure 2 . CaSki cells (10 5 ) alone or in combination with 3 Â 10 5 NAF or CAF were injected subcutaneously to the two flanks of 6B8 weeks, female NOD-SCID mice pairwisely. After 9-21 days, mice were killed and tumors were excised for analysis.
Microvessel density counting
Microvessel density in the xenograft tumor was examined by immunofluorescence staining of CD31 (Abcam, Taipei, Taiwan). For microvessel density counting, three randomly selected fields were measured for the CD31-positive pixel area by using the ImageJ program. Effect of miR-126 on tumor growth and vasculature were evaluated by adding 100 nM miR-126 precursor (AM17100; Ambion) or a negative control (AM17110; Ambion) in 20% Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) to the CaSki cell-fibroblast mix or CaSki cell alone, and were subjected to xenograft injection.
Evans blue assay
Evans blue dye was tail-vein-injected in a 35 mg/kg dose for the examination of tumor vasculature. After 30 min, mice were killed and tumor masses were excised and weighted. Retained Evans blue in the tumor was extracted by pure formamide at 56 1C for 16 h, and the amount was quantitated by spectrophotometry at 620 nm. Relative level of Evans blue per tumor weight was compared.
Tube formation assay HUVEC cells were transiently transfected with a negative control (AM17010; Ambion), or 10 or 30 nM miR-126 inhibitor (AM17000; Ambion). After 48 h incubation, transfected HUVEC cells were seeded on matrigelcoated m-slide (iBidi GmbH, Martinsried, Germany) with serum-free endothelial cell medium for tube formation assay. Treatment of 10 nM, 100 nM ADM peptide (A2327; Sigma-Aldrich, St Louis, MO, USA) or 1 mM ADM antagonist (ADM 22-52, A3832; Sigma-Aldrich) on HUVEC cells was performed during tube formation assay. After 16 h, images of the tube formation network were retrieved using an inverted phase-contrast microscope, and were quantitated by Wimasis image analysis (https:// mywim.wimasis.com/). Parameters, including loop numbers, branch points and total tube lengths, were quantitated and were transformed into percentage relative to negative control. Figure 7 . Expression of ADM in cervical cancer stroma was regulated by miR-126. (a) Levels of miR-126 and ADM mRNA were compared in grossly dissected normal stroma (n ¼ 8) and cancer stroma (n ¼ 5) of the cervix. The level of miR-126 was lower in cancer stroma than that in normal stroma, whereas that of ADM mRNA was opposite. (b) Expressional level of miR-126 in the epithelium and stroma of cervical lesions of different severity was measured. Cell populations adjacent to the basement membrane in the deep epithelium (DE) and the near stroma (NS) (black arrows), each included about six layers of cells, were microdissected from one normal cervix, two carcinoma in situ (CIS-1 and CIS-2) and one microinvasive squamous carcinoma of the cervix (upper panel). In the normal and CIS cervixes, miR-126 was highly expressed in the NS, but was dramatically downregulated in that of microinvasive cancer. Luciferase reporter assay A fragment of wild-type or mutant ADM 3 0 -untranslated region sequences containing the miR-126-binding site were formed by annealing two synthesized oligonucleotides. The two oligonucleotides for the wild-type fragment were: 5 0 -CTAGTATTCCATCATCATCACCAAGGGTGATAGCCAGCCT GCTGA-3 0 and 5 0 -AGCTTCAGCAGGCTGGCTATCACCCTTGGTGATGATGATGG AATA-3 0 , and for the mutant fragment were: 5 0 -CTAGTATTCCATCATCATCG AACCGGACGCGCGCCAGCCTGCTGA-3 0 and 5 0 -AGCTTCAGCAGGCTGGCGCG CGTCCGGTTCGATGATGATGGAATA-3 0 , respectively. The fragments were subsequently cloned downstream to a pMIR reporter plasmid (Ambion). HeLa cells were cotransfected with 400 ng of cloned reporter plasmid and 40 ng of control renilla plasmid using Lipofectamine 2000 (Invitrogen). To assess the effect of miR-126 on the reporter expression, miR-126 precursor was also transfected into the HeLa cells. Twenty-four hours after transfection, activities of luciferase and renilla were analyzed by DualLuciferase reporter assay system (Promega Biosciences, San Luis Obispo, CA, USA) by microplate luminometer.
Enzyme immunoassay
Secreted ADM was detected in conditioned media from MDA-MB-231 cells and HUVEC cells by using competitive enzyme immunoassay kit (Phoenix Pharma, Burlingame, CA, USA). MDA-MB-231 cells were transiently transfected with negative control, 10 or 30 nM miR-126 precursor by RNAiMAX (Invitrogen), and was cultured in serum-free medium for 24 h. Conditioned media were collected and concentrated by using Amicon Ultra-0.5 filter (Millipore Corporation, Chicago, IL, USA). HUVEC cells were transiently transfected with negative control, 10 or 30 nM miR-126 inhibitor by RNAiMAX (Invitrogen), and were subjected to tube formation assay. Conditioned mediums from HUVEC cells were collected after tube formation assay and were analyzed for functional ADM peptide. Concentration of ADM peptide was calculated by standard curve included in the kit following the manufacturer's protocol.
Laser-capture microdissection
Fresh, frozen tissues of one normal cervix, two CIS and one invasive squamous cell carcinoma (stage IIB) were embedded in optical coherence tomography, and serial cryosections were made in an RNAase-free condition. Parallel sections were stained with hematoxylin/eosin for histology confirmation. Areas of interest in the epithelium and stroma were retrieved by the laser-capture microdissection machine (Arcturus; PixCell, Santa Clara, CA, USA). Captured tissues of 3B5 parallel slides were pooled, and total RNA was immediately extracted using RNAqueous-Micro kit (Ambion).
Immunofluorescence staining of CD31, ADM and LYVE-1 Serial cryosection (8 mm thin) of optical coherence tomography-embedded tissues was fixed in acetone and incubated with antibodies for CD31 (Abcam), ADM (Santacruz, Santa Cruz, CA, USA) and LYVE-1 (Abcam) in a ratio of 1:200. Primary antibodies were detected by second Alexafluor dyeconjugated antibodies and mounted in Prolong gold antifade reagent (Invitrogen), and were photographed using Zeiss Axiovert 200M inverted microscope or LSM 510 Meta Confocal Microscope (Carl Zeiss, Goettingen, Germany).
